RxDoctor Payments Data

Kenneth Coleman, MD

Cardiovascular Disease · Schenectady, NYNPI 1255383774

Payments from drug & device makers

$600in general payments, 2019–2025

Across 21 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$185
  • Novartis$84
  • Johnson & Johnson$78
  • Baxter Healthcare$73
  • Boehringer Ingelheim$47
  • Abbott$21
  • plus $112 from 7 others

What the payments were for

  • Food & beverage$51385%
  • Education$142%
  • Other$7312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$600 in reported general payments places this provider in the 30th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$172,207
Medicare patients
1,042
Services billed
2,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban652$913,625
Repatha SureclickEvolocumab175$214,055
MounjaroTirzepatide167$186,596
EntrestoSacubitril/Valsartan82$137,805
JardianceEmpagliflozin81$111,731
FarxigaDapagliflozin Propanediol62$81,591
OzempicSemaglutide33$57,169
XareltoRivaroxaban33$42,642
BrilintaTicagrelor44$42,282
Ezetimibe714$30,457
Praluent PenAlirocumab40$25,743
Rosuvastatin Calcium811$20,332
WegovySemaglutide14$18,248
Eplerenone206$16,291
Atorvastatin Calcium1,028$15,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$84$137,80582 claims
AstraZenecaFarxiga, Brilinta$14$123,873106 claims
Boehringer IngelheimJardiance$47$111,73181 claims
Johnson & JohnsonXarelto$78$42,64233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →